Literature DB >> 8843311

Clarithromycin does not affect phosphorylation of zidovudine in vitro.

K Z Rana1, J W Darnowski, A H Strayer, M N Dudley.   

Abstract

Zidovudine (ZDV) and clarithromycin (CLR) are often used simultaneously in the management of patients with AIDS. While pharmacokinetic studies show decreased absorption of ZDV when it is administered with CLR, it is unknown if CLR affects the intracellular metabolism of ZDV. We investigated the effects of CLR on the intracellular metabolism of ZDV in vitro. CEM-T4 cells were coincubated with a microM ZDV ([3 H] ZDV, 3 microCi/ml) either alone or with 1 or 10 microM CLR. Cells were also grown in the presence of CLR for 48 h prior to exposure to ZDV. Samples were analyzed for mono-, di-, and triphosphate metabolites of [3 H] ZDV by high-performance liquid chromatography separation and radiochemical detection. There were no significant differences in levels of intracellular metabolites of ZDV following exposure to ZDV, either alone or with 1 or 10 microM CLR and under both coincubated and preincubated conditions. These results show that treatment with CLR does not alter the formation of phosphorylated metabolites of ZDV in this cell line.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843311      PMCID: PMC163447     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

2.  Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo.

Authors:  P Tosi; P Calabresi; F A Goulette; C A Renaud; J W Darnowski
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

3.  Biochemical pharmacology of zidovudine in human T-lymphoblastoid cells (CEM).

Authors:  V I Avramis; W Markson; R L Jackson; E Gomperts
Journal:  AIDS       Date:  1989-07       Impact factor: 4.177

4.  Penetration of macrolides into human polymorphonuclear leucocytes.

Authors:  M Ishiguro; H Koga; S Kohno; T Hayashi; K Yamaguchi; M Hirota
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

5.  Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal.

Authors:  J D Unadkat; A C Collier; S S Crosby; D Cummings; K E Opheim; L Corey
Journal:  AIDS       Date:  1990-03       Impact factor: 4.177

6.  Single- and multiple-dose pharmacokinetics of clarithromycin, a new macrolide antimicrobial.

Authors:  S Chu; D S Wilson; R L Deaton; A V Mackenthun; C N Eason; J H Cavanaugh
Journal:  J Clin Pharmacol       Date:  1993-08       Impact factor: 3.126

Review 7.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

8.  The development of macrolides: clarithromycin in perspective.

Authors:  H C Neu
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent.

Authors:  R Anderson; G Joone; C E van Rensburg
Journal:  J Antimicrob Chemother       Date:  1988-12       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.